Self-adaptive pyroptosis-responsive nanoliposomes block pyroptosis in autoimmune inflammatory diseases

• DOI: 10.1016/j.bioactmat.2024.02.022
• Publication Date: 2024-03-08T00:09:51Z
• Authors: Kaiwang Xu; Huang Yang; Jinghua Fang; Kaijie Qiu; Haotian Shen; Guanrui Huang; Qiangqiang Zheng; Canlong Wang; Tengjing Xu; Xinning Yu; Jiajie Wang; Yunting Lin; Jiacheng Dai; Yuting Zhong; Hongyun Song; Sunan Zhu; Siheng Wang; Zhuxing Zhou; Guang Yang; Zhengwei Mao; Zongyou Pan; Xuesong Dai
• Keywords: Pyroptosis; Phospholipidosis; Phosphorylcholine

Nanoliposomes have a broad range of applications in the treatment autoimmune inflammatory diseases because their ability to considerably enhance drug transport. For clinical application, nanoliposomes must be able realize on-demand release drugs at disease sites maximize drug-delivery efficacy and minimize side effects. Therefore, responsive drug-release strategies for inflammation been explored; however, no specific design has realized system based on pyroptosis-related inflammation. Herein, we report pioneering strategy self-adaptive pyroptosis-responsive liposomes (R8-cardiolipin-containing encapsulating dimethyl fumarate, RC-NL@DMF) that precisely encapsulated anti-pyroptotic into pyroptotic cells. The activated key protein,